HHC
ARRY

Hutchin Hill Capital’s Array Biopharma Inc ARRY Stock Holding History

Hutchin Hill Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-18,600
Closed -$156K – 1078
2017
Q2 		$156K Buy
+18,600
New +$152K 0.01% 803

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Hutchin Hill Capital's ARRY Position: Q3 2017 in Review

Hutchin Hill Capital sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 18,600 shares — an estimated $156K sold.

Hutchin Hill Capital first reported a position in ARRY in Q2 2017 and held it in 1 quarter. The position peaked at $156K in Q2 2017. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

  • Hutchin Hill Capital reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 18,600 Array Biopharma Inc shares in Q3 2017, an estimated $156K.
  • Hutchin Hill Capital first reported a position in Array Biopharma Inc in Q2 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Array Biopharma Inc position peaked at $156K in Q2 2017.
  • 184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.